BioSpace News Archive

Enzyme replacement therapy is the process of replacement of enzymes with artificial enzymes in patients who are suffering from deficiency of enzymes.

High resolution melt (HRM) analysis is a powerful technique in molecular biology for the detection of mutations, polymorphisms and epigenetic differences in double-stranded DNA samples.

Researchers with Google Health, Naval Medical Center San Diego (NMCSD), and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) have developed artificial intelligence (AI) models to predict status of three important biomarkers from routine breast cancer haematoxylin and eosin-stained slides, enabling better understanding of the links between biological factors for treatment and the structure (morphology) of a tumor.

Wise Therapeutics (Wise), a developer of game-based digital therapeutics, announced the results of a study conducted in collaboration with NYU Langone Health, published in Frontiers in Neurology.

Rise in geriatric population and increase in chronic diseases related to orthopedics such as osteoarthritis, traumatic fractures, osteopenia, and others are play a major role in the growth of the orthopedic device market.

Increase in geriatric population, surge in prevalence of rare diseases, rise in usage of immunoglobulins in areas of medicine, and upsurge in number of plasma collection centers drive the growth of the global plasma fractionation market.

Flood in number of patients experiencing respiratory sickness, improvements in Cough syrup item, and development in older populace drive the development of the worldwide Cough syrup market.

Valneva SE today announced the initiation of a further Phase 3 trial (VLA2001-304) for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the appointment of Moises V. “Moe” Vela, Jr. to its business advisory board.

Swing Therapeutics announced today that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to the company’s digital therapeutic for the management of fibromyalgia.